N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
N/A N=323 Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 2 N=46 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Phase 3 N=600 Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
Lymphoma · Infection · Leukemia
Primary: Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant — 74.9; 78.2…
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Phase 3 N=459 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
Phase 3 N=292 Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Fungal Infection · Hematopoietic and Lymphoid Cell Neoplasm
Primary: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI) — 1.4; 1.4 percentage of patients
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
Phase 4 N=200 Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Mycoses · Fungemia · Central Nervous System Fungal Infections
Primary: Frequency of Fungal Infection — 5; 8 participants
Phase 2 N=20 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis
Primary: Safety and Tolerability of Adjunctive Deferasirox Therapy in Patients Being Treated With LAmB for Mucormycosis
Phase 4 N=206 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants
Phase 2 N=203 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Invasive Fungal Infections
Primary: Data Review Committee (DRC) Adjudicated Overall Response at Day 42 — 28.7 Response rate percentage
Phase 2 N=112 Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Invasive Fungal Infection — 3; 4; 2 participants
Phase 2 N=219 Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Phase 3 N=199 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
Phase 3 N=450 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Candidiasis, Invasive · Candidemia · Mycoses
Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Phase 3 N=527 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Aspergillosis · Invasive Fungal Infection
Primary: All-cause Mortality Through Day 42 — 18.6; 20.2 percentage of participants
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 3 N=252 Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
Leukopenia
Primary: Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period — 4; 11 participants
N/A N=23 A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
Systemic Fungal Infections
Primary: Diagnosis of Systemic Fungal Infection (SFI) — 20; 6; 18; 3 Participants
Phase 4 N=35 Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over…
Phase 3 N=62 Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
Fungal Infection
Primary: Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment — 6; 32; 11; 10 Participants
Phase 3 N=489 Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Antifungal Prophylaxis of Invasive Fungal Infections
Primary: Success at Day 180: Percent of Responders (Randomization Strata) — 59.1; 44.7; 52.5; 25.9 percent of participants
Phase 3 N=355 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
Invasive Fungal Disease
Primary: Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) — 7.9; 11.7 percentage of…